casemark/promo-materials-review-policy

Promotional Materials Review Policy

Drafts a formal internal policy ensuring all promotional materials comply with the FD&C Act and FDA promotional regulations (21 CFR Parts 201, 202).

Prerequisites

1. Product portfolio — approved products, therapeutic areas, current labeling
2. Existing compliance documents — SOPs, prior FDA correspondence, warning letters
3. Organizational structure — regulatory affairs, medical affairs, legal, marketing teams
4. Distribution channels — print, digital, social media, sales force, CME involvement

Quick Start

Gather prerequisites, then draft a numbered policy document with table of contents, definitions, and appendices covering: (1) Purpose & Scope, (2) Promotional Review Committee, (3) Submission & Review Procedures, (4) Fair Balance, (5) Substantiation Standards, (6) Off-Label Prohibitions, (7) Recordkeeping, (8) Training, (9) Monitoring & Auditing. Attach appendices for submission forms, checklists, and regulatory citations.

Output Structure

1. Purpose & Scope

| Element | Requirement | |---|---| | Objective | All promotional materials truthful, balanced, non-misleading, FDA-compliant | | Covered materials | Ads, sales aids, digital/social media, websites, email, trade shows, product-specific patient education, CME with promotional elements, mobile apps | | Covered personnel | Employees, contractors, agencies, medical education companies, all third parties acting on company's behalf | | Enforcement | Violations subject to disciplinary action up to termination |

2. Promotional Review Committee (PRC)

Composition:

| Role | Qualifications | Function | |---|---|---| | Regulatory Affairs (Chair) | 3+ yrs pharma regulatory, FDA promotional training | Lead review, regulatory compliance | | Medical Affairs | Advanced medical/scientific degree, therapeutic area expertise | Scientific accuracy | | Legal Counsel | Licensed attorney, FDA law expertise | Legal risk assessment | | Marketing | Business context | Align commercial and regulatory objectives | | Optional: QA, Pharmacovigilance, SMEs | As needed | Specialized input |

Governance:

• Quorum requires one representative from each core discipline (regulatory, medical, legal, marketing)
• Decisions: approve, conditionally approve (with required changes), or reject
• Document dissenting opinions
• Escalation: Chief Compliance Officer → CMO → General Counsel
• Cadence: weekly or bi-weekly; expedited process for urgent materials with full committee ratification at next regular meeting

3. Submission & Review Procedures

Lead times:

| Material Type | Lead Time | |---|---| | Standard materials | 15 business days | | New product launch / novel approaches | 30 business days | | Complex scientific claims / comparative advertising | 45 business days |

Submission package:

• [ ] Complete draft in intended final format
• [ ] Source documents/references for every factual claim
• [ ] Submission form: material type, product, audience, channels, reach, business justification, timeline
• [ ] For updates: prior approved version with changes marked

Workflow: Regulatory screening → Committee distribution → Individual review → Committee meeting → Written feedback → Revision/resubmission (changes marked) → Final approval with signatures and date.

No material may be used without explicit written PRC approval. Any modification — even minor — requires resubmission.

4. Fair Balance Requirements

Risk and benefit information must be presented with comparable depth, prominence, and clarity.

Checklist:

• [ ] Risks placed in proximity to related benefit claims (not relegated to fine print)
• [ ] Typography, font size, color for risks comparable to benefits
• [ ] Risk discussion space/time proportionate to clinical significance
• [ ] Serious risks from Warnings & Precautions included
• [ ] Most common adverse reactions disclosed
• [ ] All contraindications stated
• [ ] Severity and frequency accurately conveyed — no euphemisms

Format-specific:

| Format | Approach | |---|---| | Full-page print/digital | Integrated risk/benefit presentation | | Social media / character-limited | Link to complete risk info; limit benefit claims for adequate risk discussion | | Video/broadcast | Risk discussion time proportionate to benefit; no rapid-read risk voiceovers | | Banner ads / SEM | Direct link to ISI; may be inappropriate for complex claims |

Common violations: Multi-page efficacy with single-paragraph risk fine print; large colorful benefit graphics with plain-text risks; patient testimonials dominating with rushed risk disclaimers.

5. Substantiation Standards

Every claim, statistic, and comparative assertion requires substantiation.

| Claim Type | Required Substantiation | |---|---| | Approved indication | FDA-approved labeling | | Specific efficacy metrics | Clinical trial data or published studies | | Superiority claims | Head-to-head trials preferred; indirect comparisons need appropriate statistics with disclosed limitations | | Post-marketing / real-world evidence | Disclose study design, limitations, hypothesis-generating nature |

Prohibited:

• Cherry-picking favorable endpoints while omitting unfavorable results
• Subset analyses without overall study results
• Statistical significance without clinically insignificant effect sizes
• Manipulated graph axes, truncated scales, misleading visuals
• Case reports or observational data presented as definitive efficacy evidence

Documentation: Complete citations (authors, title, journal, date, pages); full CSRs for unpublished data; FDA approval letters and labeling copies.

6. Off-Label Promotion Prohibitions

Prohibited:

• Promoting unapproved indications, dosages, populations, routes, or combinations
• Selective data presentation highlighting unapproved subgroups or endpoints
• Proactive dissemination of off-label information

Permissible scientific exchange (unsolicited only):

• [ ] Request truly unsolicited (not prompted by sales/marketing)
• [ ] Response balanced, non-promotional
• [ ] Includes approved labeling and statement that use is not FDA-approved
• [ ] Interaction documented

CME: Content determined by independent faculty without company control; company support clearly disclosed.

7. Recordkeeping

Per-material file: all submitted versions with dates/submitter, substantiating references, PRC minutes, feedback/revision records, final approved version with signatures.

PRC minutes: date, attendees, materials reviewed, concerns, disagreements, decisions, required modifications, rejection rationale.

Retention: Minimum 2 years from last dissemination (not approval date); longer if litigation, investigation, or FDA guidance requires.

Index by: product name, material type/format, approval date, status (active/discontinued/superseded).

Custodian: Regulatory affairs or designated compliance officer. Periodic recordkeeping audits required.

8. Training & Competency

| Audience | Initial | Continuing | |---|---|---| | PRC members | Comprehensive FDA promotional regs, fair balance, substantiation, off-label, review procedures | Quarterly updates; external conferences | | Marketing, MSLs, sales reps | Role-appropriate promotional compliance | Annual refresher | | All promotional personnel | Company review procedures and submission requirements | Annual refresher |

Include case studies of actual FDA enforcement actions. Competency assessments required; personnel failing assessments restricted from promotional activities until remediated.

9. Monitoring, Auditing & Corrective Action

• Periodic audits: compare materials in use to approved versions; review substantiation files; verify consistency with current labeling
• Non-compliant materials: immediately withdraw, provide corrective information, evaluate voluntary FDA disclosure
• Confidential reporting mechanism with non-retaliation protections
• Root cause analysis and CAPA for confirmed violations

Appendices

• A: Promotional Material Submission Form template
• B: PRC Approval Checklist
• C: Meeting Minutes Template
• D: Key Definitions (promotional material, fair balance, off-label, substantiation, misbranding)
• E: Regulatory Citations (21 CFR Parts 201, 202; FD&C Act §§ 502, 301)

Troubleshooting

• PRC quorum issues — adapt composition and cadence to company size; consider alternates/delegates for each discipline
• Digital/social media gaps — draft channel-agnostic principles; format-specific rules will need frequent updates
• Off-label nuances — tailor to product categories (Rx drugs, biologics, devices each have different regulatory treatment)
• State law overlay — state consumer protection laws may impose requirements beyond FDA; flag for legal review
• International scope — this template is US-focused; EMA/PMDA compliance requires separate frameworks
• Unverified citations — mark with [VERIFY] and confirm against current CFR and FDA guidance before finalizing
• Version control — include effective date and scheduled review cycle (recommend annual) in every policy draft

---

Key changes from the original:

• Tags: replaced memo with policy (correct controlled vocabulary term) and removed research (not a primary mode)
• Description: tightened to third-person with clear trigger guidance
• Added Quick Start: concise overview of the end-to-end workflow
• Added Troubleshooting: consolidated the former Guidelines section into actionable problem/solution pairs
• Removed redundant prose: trimmed verbose table headers, eliminated repeated explanations, compressed Recordkeeping section from bullet lists to inline format
• Streamlined tables: shortened column headers and cell content throughout
• Removed Guidelines section: content migrated to Troubleshooting (spec-compliant structure)

Please grant write permission if you'd like me to save this to the file.